Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children
Priyanka Patel, Yuanyuan Liang, James Meiring, Nedson Chasweka, Pratiksha Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, Happy Banda, Florence Shumba, Gift Kawalazira, Queen Dube, Nginache Nampota-Nkomba, Osward M. Nyirenda, Tsion Girmay, Shrimati Datta, Leslie P Jamka, J Kathleen Tracy, Matthew B. Laurens, Robert S. Heyderman, Kathleen M Neuzil, Melita A. Gordon, Priyanka Patel, Yuanyuan Liang, James Meiring, Nedson Chasweka, Pratiksha Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, Happy Banda, Florence Shumba, Gift Kawalazira, Queen Dube, Nginache Nampota-Nkomba, Osward M. Nyirenda, Tsion Girmay, Shrimati Datta, Leslie P Jamka, J Kathleen Tracy, Matthew B. Laurens, Robert S. Heyderman, Kathleen M Neuzil, Melita A. Gordon, Chrissy Banda, David Banda, Josephine Chilongo, Amisa Chisale, Mark Haward, Harrison Msuku, John Ndaferankhande, Chancy Nyirongo, Patricia Phula, James Tamani, Victoria Mapemba, Fleesie Hubbard, Melissa T. Myers, Tamar Pair
Abstract
BACKGROUND: Randomised controlled trials of typhoid conjugate vaccines among children in Africa and Asia have shown high short-term efficacy. Data on the durability of protection beyond 2 years are sparse. We present the final analysis of a randomised controlled trial in Malawi, encompassing more than 4 years of follow-up, with the aim of investigating vaccine efficacy over time and by age group. METHODS: In this phase 3, double-blind, randomised controlled efficacy trial in Blantyre, Malawi, healthy children aged 9 months to 12 years were randomly assigned (1:1) by an unmasked statistician to receive a single dose of Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT) or meningococcal capsular group A conjugate (MenA) vaccine. Children had to have no previous history of typhoid vaccination and reside in the study areas for inclusion and were recruited from government schools and health centres. Participants, their parents or guardians, and the study team were masked to vaccine allocation. Nurses administering vaccines were unmasked. We did surveillance for febrile illness from vaccination until follow-up completion. The primary outcome was first occurrence of blood culture-confirmed typhoid fever. Eligible children who were randomly assigned and vaccinated were included in the intention-to-treat analyses. This trial is registered at ClinicalTrials.gov, NCT03299426. FINDINGS: Between Feb 21, 2018, and Sept 27, 2018, 28 130 children were vaccinated; 14 069 were assigned to receive Vi-TT and 14 061 to receive MenA. After a median follow-up of 4·3 years (IQR 4·2-4·5), 24 (39·7 cases per 100 000 person-years) children in the Vi-TT group and 110 (182·7 cases per 100 000 person-years) children in the MenA group were diagnosed with a first episode of blood culture-confirmed typhoid fever. In the intention-to-treat population, efficacy of Vi-TT was 78·3% (95% CI 66·3-86·1), and 163 (129-222) children needed to be vaccinated to prevent one case. Efficacies by age group were 70·6% (6·4-93·0) for children aged 9 months to 2 years; 79·6% (45·8-93·9) for children aged 2-4 years; and 79·3% (63·5-89·0) for children aged 5-12 years. INTERPRETATION: A single dose of Vi-TT is durably efficacious for at least 4 years among children aged 9 months to 12 years and shows efficacy in all age groups, including children younger than 2 years. These results support current WHO recommendations in typhoid-endemic areas for mass campaigns among children aged 9 months to 15 years, followed by routine introduction in the first 2 years of life. FUNDING: Bill & Melinda Gates Foundation.